[go: up one dir, main page]

AR001435A1 - Utilizacion de al menos un antagonista de cgrp en y/o para la preparacion de una composicion cosmetica, farmaceutica y/o dermatologica para tratar losliquenes, los prurigos, las toxidermias pruriginosas y los pruritos severos. - Google Patents

Utilizacion de al menos un antagonista de cgrp en y/o para la preparacion de una composicion cosmetica, farmaceutica y/o dermatologica para tratar losliquenes, los prurigos, las toxidermias pruriginosas y los pruritos severos.

Info

Publication number
AR001435A1
AR001435A1 ARP960101927A AR10192796A AR001435A1 AR 001435 A1 AR001435 A1 AR 001435A1 AR P960101927 A ARP960101927 A AR P960101927A AR 10192796 A AR10192796 A AR 10192796A AR 001435 A1 AR001435 A1 AR 001435A1
Authority
AR
Argentina
Prior art keywords
pruritic
cosmetic
pharmaceutical
severe
prurity
Prior art date
Application number
ARP960101927A
Other languages
English (en)
Inventor
Lacharriere Olivier De
Lionel Breton
Original Assignee
L'oréal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9477497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR001435(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by L'oréal filed Critical L'oréal
Publication of AR001435A1 publication Critical patent/AR001435A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La invención se refiere a la utilización de un antagonista de CGRP en una composición cosmética, farmacéutica o dermatológica, en especial paraaplicación tópica para tratar los líquenes, los prurigos, las toxidermias pruriginosas y los pruritos severos.
ARP960101927A 1995-03-28 1996-03-27 Utilizacion de al menos un antagonista de cgrp en y/o para la preparacion de una composicion cosmetica, farmaceutica y/o dermatologica para tratar losliquenes, los prurigos, las toxidermias pruriginosas y los pruritos severos. AR001435A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503627A FR2732220B1 (fr) 1995-03-28 1995-03-28 Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue

Publications (1)

Publication Number Publication Date
AR001435A1 true AR001435A1 (es) 1997-10-22

Family

ID=9477497

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101927A AR001435A1 (es) 1995-03-28 1996-03-27 Utilizacion de al menos un antagonista de cgrp en y/o para la preparacion de una composicion cosmetica, farmaceutica y/o dermatologica para tratar losliquenes, los prurigos, las toxidermias pruriginosas y los pruritos severos.

Country Status (14)

Country Link
US (1) US5935586A (es)
EP (1) EP0734728B2 (es)
JP (1) JP3043610B2 (es)
AR (1) AR001435A1 (es)
AT (1) ATE201828T1 (es)
BR (1) BR9601467A (es)
CA (1) CA2172778C (es)
DE (1) DE69613168T3 (es)
ES (1) ES2159697T5 (es)
FR (1) FR2732220B1 (es)
HU (1) HUP9600764A3 (es)
MX (1) MX9601151A (es)
PL (1) PL313511A1 (es)
RU (1) RU2152785C1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
JP2001233764A (ja) * 2000-02-22 2001-08-28 Hisamitsu Pharmaceut Co Inc Ｎ−置換−ｏ−トルイジン誘導体からなる鎮痒剤
WO2004014351A2 (en) 2002-08-12 2004-02-19 Birkir Sveinsson Use of cgrp antagonist compounds for treatment of psoriasis
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
CN101309704B (zh) 2005-11-14 2012-10-10 礼纳特神经系统科学公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
AU2010288194B2 (en) 2009-08-28 2013-08-29 Teva Pharmaceuticals International Gmbh Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
PE20191148A1 (es) 2016-09-23 2019-09-02 Teva Pharmaceuticals Int Gmbh Tratamiento de la migrana refractaria
US11433119B2 (en) 2016-11-18 2022-09-06 Nepsone Ehf Methods of treating inflammatory skin disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9201425D0 (sv) * 1992-05-06 1992-05-06 Kabi Pharmacia Ab Method and means for preventing constriction of the pupil in the eye
JP2656700B2 (ja) * 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith

Also Published As

Publication number Publication date
MX9601151A (es) 1997-02-28
EP0734728A1 (fr) 1996-10-02
PL313511A1 (en) 1996-09-30
FR2732220B1 (fr) 1997-04-25
ATE201828T1 (de) 2001-06-15
DE69613168T2 (de) 2001-09-27
CA2172778C (fr) 2008-02-12
ES2159697T5 (es) 2008-07-01
EP0734728B1 (fr) 2001-06-06
JPH08268904A (ja) 1996-10-15
JP3043610B2 (ja) 2000-05-22
DE69613168D1 (de) 2001-07-12
HUP9600764A3 (en) 1998-03-02
HUP9600764A2 (en) 1997-06-30
EP0734728B2 (fr) 2008-02-13
FR2732220A1 (fr) 1996-10-04
HU9600764D0 (en) 1996-05-28
BR9601467A (pt) 1998-03-31
ES2159697T3 (es) 2001-10-16
US5935586A (en) 1999-08-10
DE69613168T3 (de) 2009-03-05
CA2172778A1 (fr) 1996-09-29
RU2152785C1 (ru) 2000-07-20

Similar Documents

Publication Publication Date Title
ES2121461T3 (es) Utilizacion de un antagonista de cgrp para tratar el eritema cutaneo de origen neurogenico y composicion asi obtenida.
DK0723774T3 (da) Anvendelse af en antagonist for CGRP i en kosmetisk, farmaceutisk eller dermatologisk sammensætning og den opnåede sammensæ
AR001435A1 (es) Utilizacion de al menos un antagonista de cgrp en y/o para la preparacion de una composicion cosmetica, farmaceutica y/o dermatologica para tratar losliquenes, los prurigos, las toxidermias pruriginosas y los pruritos severos.
YU49315B (sh) Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
AR002007A1 (es) UNA COMPOSICION TERAPEUTICA DE APLICACION TOPICA QUE CONTIENE UN ANTAGONISTA DE SUSTANCIA P Y UTILIZACION DE DICHO ANTAGONISTA PARA LAPREPARACIóN DE DICHA COMPOSICION PARA DISMINUIR Y/O ELIMINAR UN EFECTO SECUNDARIO IRRITANTE DE UN PRODUCTO CONTENIDO EN LA MISMA.
FI883055A7 (fi) Deodoroiva ja antimikrobinen koostumus käytettäväksi kosmeettisissa tai paikallisesti käytettävissä valmisteissa.
PT729750E (pt) Composicao cosmetica farmaceutica ou dermatologica contendo um antagonista de tnf-alfa
ES2154503T3 (es) Composicion cosmetica o dermatologica.
EP0824915A3 (de) Herstellung von Glycoglycerolipiden, deren Verwendung als Tenside sowie kosmetische oder dermatologische Zubereitungen, solche Glycoglycerolipide enthaltend
BR9611377A (pt) Inibidor de trombina de ligação não lenta processo para preparar o mesmo composição farmacêutica e uso do inibidor de trombina
ATE221881T1 (de) Tetralin-verbindungen mit multi-drugresistenz (mdr)-aktivitat
BR9501815A (pt) Composição cosmética ou farmacèutica de uso tópico
AR017222A1 (es) Procedimiento de utilizacion de un agente que inhibe el desarrollo de p.ovale, en la preparacion de medicamentos
BR9604031A (pt) Uso de pelo menos um composto escolhido de antagonistas de bradiquinina uso em uma composição tópica de pelo menos um composto escolhido de antagonistas de bradiquinha processo de tratamento cosmético e composição cosmética farmacêutica ou dermatológica
BR9205201A (pt) Composicao de produto pessoal ou detergente e uso de um glicolipideo anionico
ES2143705T3 (es) Preparaciones cosmeticas y/o farmaceuticas que contienen tensioactivos sacaricos y gliceridos parciales de acidos grasos.
BR0317461A (pt) Composições tópicas absorventes de óleo e método para o uso das mesmas
ES2177098T3 (es) Utilizacion de goma y de difenildimeticona disuelta en una silicona novolatil de tipo feniltrimeticona para la fabricacion de una composicion cosmetica o farmaceutica, especialmente dermatologica que comprende una fase grasa.
AR004326A1 (es) Utilizacion de al menos un antagonista de tnf-alfa, composicion cosmetica, farmaceutica o dermatologica que contiene dicho antagonista y procedimiento detratamiento cosmetico empleando dicho antagonista.
PT101444A (pt) Associacao sinergizante com efeito antagonista dos receptores nk1 e nk2, uso de produtos com actividade antagonista dos receptores nk1 e nk2 na sua preparacao e composicao farmaceutica contendo a referida associacao
ECSP941120A (es) Derivados de 1,5 benzodiazepina
ES2163596T3 (es) Utilizacion de un antagonista de cgrp para el tratamiento de los pruritos y de las disestesias oculares o palpebrales.
PT914078E (pt) Uso de l-lisina no tratamento da perda de cabelo
ITRM950273A0 (it) Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni farmaceutiche.
YU39396A (sh) Upotreba izolovanog prirodnog proteina gojaznosti za pripremu leka i njegova farmaceutska formulacija